Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Department of Hematology, Shandong Provincial Hospital, Shandong First Medical University, Jinan, China.
Leuk Lymphoma. 2021 Jun;62(6):1335-1343. doi: 10.1080/10428194.2020.1867726. Epub 2021 Jan 5.
Diffuse large B-cell lymphoma (DLBCL) has been correlated with virus infection and immunity status. We retrospectively analyzed the association between HBV antibody and DLBCL development in HBsAg patients. Compared with HBeAb patients, HBeAb patients displayed unique clinical features. HBV antibody-negative patients had better therapeutic efficiency ( < .05). The media progression-free survival (PFS) and overall survival (OS) of HBV antibody-positive group were shorter than the negative group ( < .05). Furthermore, we found positive association between CD21 and HBsAb and their synergistic effect for prognostic predication. Interestingly, the effect of Rituximab in prognostic improvement was more significant in HBV antibody-positive group than negative group. Univariate analysis showed that HBV antibody was independent risk factor for disease prognosis. Altogether, our investigations identified for the first time the close association between HBV antibody and clinical prognosis in DLBCL patients. These findings provide potential biomarker to predict the effect of Rituximab and prognosis in DLBCL patients.
弥漫性大 B 细胞淋巴瘤（DLBCL）与病毒感染和免疫状态有关。我们回顾性分析了 HBsAg 患者中 HBV 抗体与 DLBCL 发展之间的关系。与 HBeAb 患者相比，HBeAb 患者表现出独特的临床特征。HBV 抗体阴性患者的治疗效果更好（<0.05）。HBV 抗体阳性组的中位无进展生存期（PFS）和总生存期（OS）均短于阴性组（<0.05）。此外，我们发现 CD21 和 HBsAb 之间存在正相关关系，它们对预后预测有协同作用。有趣的是，与 HBV 抗体阴性组相比，Rituximab 在改善预后方面的效果在 HBV 抗体阳性组中更为显著。单因素分析显示，HBV 抗体是疾病预后的独立危险因素。总之，我们的研究首次确定了 HBV 抗体与 DLBCL 患者临床预后之间的密切关系。这些发现为预测 Rituximab 疗效和 DLBCL 患者预后提供了潜在的生物标志物。
